Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Adult

Bhasin S, Parker RA, Sattler F, et al. "Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity." J. Clin. Endocrinol. Metab.. 2007;92(3):1049-57.
Sinxadi PZuleika, McIlleron HMargaret, Dave JAlex, et al. "Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations." Medicine (Baltimore). 2016;95(2):e2385.
Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. "The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin." Aliment. Pharmacol. Ther.. 2011;33(11):1234-44.
Schooley RT, Spritzler J, Wang H, et al. "AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein." J. Infect. Dis.. 2010;202(5):705-16.
Mitsuyasu R, Gelman R, Cherng DWeng, et al. "The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328." Arch. Intern. Med.. 2007;167(6):597-605.
Zhang X, Tierney C, Albrecht M, et al. "Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146." Ther Drug Monit. 2013;35(2):209-16.
Schifitto G, Zhang J, Evans SR, et al. "A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment." Neurology. 2007;69(13):1314-21.
Markowitz M, Vaida F, C Hare B, et al. "The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection." J. Infect. Dis.. 2010;201(9):1298-302.
Gripshover BM, Ribaudo H, Santana J, et al. "Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)." Antivir. Ther. (Lond.). 2006;11(5):619-23.
Gupta SK, Komarow L, Gulick RM, et al. "Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects." J. Infect. Dis.. 2009;200(4):614-8.
Longenecker CT, Kitch D, Sax PE, et al. "Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s." J. Acquir. Immune Defic. Syndr.. 2015;69(2):168-77.
Rosenberg ES, Graham BS, Chan ES, et al. "Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection." PLoS ONE. 2010;5(5):e10555.
Ribaudo HJ, Haas DW, Tierney C, et al. "Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study." Clin. Infect. Dis.. 2006;42(3):401-7.
F Romo T, Smeaton LM, Campbell TB, et al. "Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175)." HIV Clin Trials. 2014;15(6):246-60.
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. "Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES." PLoS ONE. 2013;8(6):e65306.
Haas DW, Kwara A, Richardson DM, et al. "Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes." J. Antimicrob. Chemother.. 2014;69(8):2175-82.
Gandhi RT, Spritzler J, Chan E, et al. "Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384." J. Acquir. Immune Defic. Syndr.. 2006;42(4):426-34.
McComsey GA, Kang M, Ross AC, et al. "Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy." HIV Clin Trials. 2008;9(2):126-36.
Hulgan T, Hughes M, Sun X, et al. "Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study." J. Acquir. Immune Defic. Syndr.. 2006;42(4):450-4.
D Watts H, Park J-G, Cohn SE, et al. "Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093." Contraception. 2008;77(2):84-90.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.
Cao YJun, Flexner CW, Dunaway S, et al. "Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers." Antimicrob. Agents Chemother.. 2008;52(5):1630-4.
Kelesidis T, Kendall MA, Yang OO, Hodis H, Currier JS. "Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study." AIDS Res. Hum. Retroviruses. 2013;29(6):938-48.
Ciaranello AL, Lockman S, Freedberg KA, et al. "First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial." AIDS. 2011;25(4):479-92.
Chen H, Clifford DB, Deng L, et al. "Peripheral neuropathy in ART-experienced patients: prevalence and risk factors." J. Neurovirol.. 2013;19(6):557-64.
Blodget E, Shen C, Aldrovandi G, et al. "Relationship between microbial translocation and endothelial function in HIV infected patients." PLoS ONE. 2012;7(8):e42624.
Liu H, Wilson IB, Goggin K, et al. "MACH14: a multi-site collaboration on ART adherence among 14 institutions." AIDS Behav. 2013;17(1):127-41.
Kojic EMilunka, Kang M, Cespedes MS, et al. "Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women." Clin. Infect. Dis.. 2014;59(1):127-35.
Hulgan T, Robbins GK, Kalams SA, et al. "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384." PLoS ONE. 2012;7(8):e43803.
Mwafongo A, Nkanaunena K, Zheng Y, et al. "Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine." AIDS. 2014;28(8):1135-42.

Pages